Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Key Inclusion Criteria: * Relapsed or refractory metastatic pancreatic adenocarcinoma * Received 1 prior chemotherapy regimen for metastatic pancreatic ductal adenocarcinoma (not including neoadjuvant and/or adjuvant therapy) * Measurable disease per RECIST v1.1 * Adequate organ function defined as * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN) OR ≤ 5 x ULN if liver metastases are present; total conjugated bilirubin ≤ 2 x ULN * Absolute neutrophil count (ANC) ≥1500 cells/mm\^3, platelet ≥100,000 cells/mm\^3, hemoglobin ≥ 9.0 g/dL * Creatinine clearance (CrCl) \> 50 ml/min as calculated by the Cockroft-Gault method * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Key Exclusion Criteria: * Received more than 1 prior line of chemotherapy for metastatic pancreatic ductal adenocarcinoma * Major surgery within 21 days of first dose of study drug * Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ≥ 1 day before enrollment is acceptable) * Chemotherapy, immunotherapy, biologics, and/or investigational therapy within 21 days prior to first dose of study drug * Known positive status for HIV, chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier * Known dihydropyrimidine dehydrogenase deficiency * Peripheral neuropathy ≥ Gr…